Physiomics Director’s Dual Role Faces Challenges as OCT Enters Administration

Physiomics ( (GB:PYC) ) has shared an update.

Physiomics plc announced an update regarding its Non-Executive Director, Dr. Timothy Corn, who is also an Executive Director at Oxford Cannabinoid Technologies Holdings plc (OCT). OCT was placed into administration on May 2, 2025. This development may impact the operations and strategic positioning of Physiomics, as it involves a key member of its board being associated with a company undergoing financial difficulties.

Spark’s Take on GB:PYC Stock

According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.

Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.

To see Spark’s full report on GB:PYC stock, click here.

More about Physiomics

Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, supporting the development of new therapeutics and personalized medicine solutions. The company helps biotech and pharma companies streamline their drug development processes by deriving insights from diverse data to optimize research design across various stages of drug development. Physiomics has contributed to over 100 commercial projects, working with clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.

Average Trading Volume: 7,079,330

Technical Sentiment Signal: Sell

Current Market Cap: £1.35M

For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.